Come and Meet LFB Group at BIO 2011 in Washington (French Pavilion Hall B - Booth 2025)

LFB is a European Biopharmaceutical Group that develops, manufactures and markets Medicinal Products for the treatment of serious and often rare diseases in several major therapeutic fields, namely Immunology, hemostasis, and intensive care

PARIS--(BUSINESS WIRE)-- LFB, the French Biopharmaceutical Group will be attending to the BIO2011 international convention in Washington to find:

- Partners to co-develop its monoclonal antibodies (anti-CD20, anti-D) and recombinant transgenic proteins (ATryn®, FVIIa, FIX, AFP, Alpha-1-antitrypsin) from GTC – LFB US subsidiary and/or for out-licensing deals.

- Innovative technologies in the fields of cell line development, and purification of monoclonal antibodies and recombinant proteins.

- Commercial partnerships for licensing-in hospital products for short term launch in France.

- Commercial partnership for licensing out our product line.

- Collaborations and CMO services for MAbgène, its GMP biomanufacturing affiliate (CMO).

LFB’s key achievements in 2010 / 2011

Products marketing

Completion of the acquisition of GTC Biotherapeutics by LFB Biotechnologies in December 2010

Marketing of ATryn® in the United States through LFB‘s US subsidiary GTC BIOTHERAPEUTICS Inc.

Launch of CLAIRYG®, a new liquid intravenous immunoglobulin in France.

LFB BIOMEDICAMENTS S.A. received a positive evaluation from the European regulatory authorities as a result of the WILLFACT® 1000 lU mutual recognition registration procedure, with Germany acting as the Reference Member State.

LFB BIOTECHNOLOGIES S.A.S and THALLION PHARMACEUTICALS Inc. signed an agreement over the development and marketing of SHIGAMABS®.

THALLION PHARMACEUTICALS Inc. has granted LFB BIOTECHNOLOGIES S.A.S. an exclusive license for the commercial rights to SHIGAMABS® in Europe, South America and certain territories that are of strategic importance to LFB Group, including Russia, China, South Korea and North Africa. THALLION PHARMACEUTICALS Inc., however, has retained the commercial rights for North America and the rest of the world.

Launch of Phase II of SHIGAMABS® in partnership with THALLION PHARMACEUTICALS Inc. The Phase II “SHIGATEC” trial to evaluate SHIGAMABS® as a treatment for Shiga toxin producing E.Coli (STEC) bacterial infections was launched in South America.

LFB BIOTECHNOLOGIES recombinant humanized Anti-CD20 monoclonal antibody was granted orphan drug status by the FDA for the treatment of Chronic Lymphoid Leukaemia (CLL)

Biomanufacturing

Partnership agreement in the area of bioproduction in France between LFB BIOTECHNOLOGIES S.A.S. and SANOFI CHIMIE S.A. and creation of a JV (under the structure of an Economic Interest Group - EIG) named LFB BIOTECHNOLOGIES-SANOFI CHIMIE.

Operational start-up of new bioproduction capacities at the MAbgène SAS site (Alès, France) .

The introduction of the single-use 1000 l bioreactor technology has significantly increased the site's industrial efficiency. These new capacities will enable the production of clinical batches as well as future commercial batch orders.

About the LFB Group

LFB is a biopharmaceutical group that develops, manufactures and markets medicinal products for the treatment of serious and often rare diseases in several major therapeutic fields, namely immunology, hemostasis and intensive care. LFB Group is the leading manufacturer of plasma-derived medicinal products in France and 6th worldwide and is also among the leading European companies for the development of monoclonal antibodies and new-generation proteins based on biotechnologies. With its strong focus on research, the LFB Group is pursuing a growth strategy that seeks to extend its activities at international level and develop innovative therapies.

In 2010, LFB’s turnover reached € 411.6 million; €86.5 million were dedicated to the group’s R&D activities. Christian Béchon is President and CEO of the LFB Group (1 835 employees).

http://www.lfb.fr



CONTACT:

LFB
Gail SOUBIES
Corporate Communications Assistant
LFB SA
Tel: + 33 (0)1.69.82.88.69
Mob: +33 (0)6 78 66 49 96
Email: [email protected]

KEYWORDS:   United States  Europe  North America  District of Columbia  France

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Pillar is bankrolling a new accelerator for budding biotechs. Petri aims to serve biotech startups at the “frontier of biology and engineering.”

One of the last major, late-stage attempt at stopping Alzheimer’s using a BACE inhibitor has ended up on the trash pile with so many others.

The oligosaccharide microbiome modulator was no better than placebo at reducing lactose intolerance symptoms.